- Home
- PTHL vs UCL Comparison
PTHL vs UCL Comparison
Compare PTHL & UCL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PTHL
- UCL
- Stock Information
- Founded
- PTHL 1998
- UCL 2014
- Country
- PTHL China
- UCL Hong Kong
- Employees
- PTHL N/A
- UCL N/A
- Industry
- PTHL
- UCL Telecommunications Equipment
- Sector
- PTHL
- UCL Consumer Discretionary
- Exchange
- PTHL Nasdaq
- UCL Nasdaq
- Market Cap
- PTHL 85.4M
- UCL 70.6M
- IPO Year
- PTHL 2024
- UCL 2020
- Fundamental
- Price
- PTHL $1.65
- UCL $2.80
- Analyst Decision
- PTHL
- UCL
- Analyst Count
- PTHL 0
- UCL 0
- Target Price
- PTHL N/A
- UCL N/A
- AVG Volume (30 Days)
- PTHL 2.3M
- UCL 132.6K
- Earning Date
- PTHL 02-11-2025
- UCL 08-13-2025
- Dividend Yield
- PTHL N/A
- UCL N/A
- EPS Growth
- PTHL N/A
- UCL N/A
- EPS
- PTHL N/A
- UCL 0.09
- Revenue
- PTHL $448,196.00
- UCL $92,256,000.00
- Revenue This Year
- PTHL N/A
- UCL $6.09
- Revenue Next Year
- PTHL N/A
- UCL $7.01
- P/E Ratio
- PTHL N/A
- UCL $30.77
- Revenue Growth
- PTHL N/A
- UCL 7.65
- 52 Week Low
- PTHL $1.32
- UCL $0.80
- 52 Week High
- PTHL $32.00
- UCL $3.30
- Technical
- Relative Strength Index (RSI)
- PTHL N/A
- UCL 68.71
- Support Level
- PTHL N/A
- UCL $1.82
- Resistance Level
- PTHL N/A
- UCL $2.99
- Average True Range (ATR)
- PTHL 0.00
- UCL 0.28
- MACD
- PTHL 0.00
- UCL 0.06
- Stochastic Oscillator
- PTHL 0.00
- UCL 83.76
About PTHL Pheton Holdings Ltd Class A Ordinary Shares
Pheton Holdings Ltd is a healthcare solutions provider dedicated to developing and commercializing treatment software and devices used for brachytherapy. Its proprietary treatment planning system is a type of radiation therapy used in treating cancer patients by placing radioactive sources inside the patient that kill cancer cells and shrink tumors. Its proprietary treatment planning system, FTTPS, is designed to promote the efficiency, accuracy, and safety of brachytherapy. FTTPS is a user-oriented treatment planning system, or TPS, for treating a wide variety of malignant tumors, which can determine the target volume, prescription dose, and dose limitation to protect OARs and produce a safe, effective, and accurate dose distribution plan for brachytherapy for cancer patients.
About UCL uCloudlink Group Inc.
Ucloudlink Group Inc is engaged in the provision of data connectivity services and sales of Wi-Fi terminals and data related products to enable personal and enterprise users to access mobile internet in more than 100 countries and areas. Leveraging its inventive cloud SIM technology and architecture, the company redefine the mobile data connectivity experience, allowing users to gain access to mobile data traffic allowance shared by network operators on its marketplace. It has aggregated mobile data traffic allowances from 391 MNOs in 163 countries and regions in its cloud SIM architecture. The company derives maximum revenue from Japan.